Delving into the Latest Updates on Recombinant cytokine gene derived protein(Genova, Inc.) with Synapse

This work aimed to show which treatments showed efficacy against coronavirus disease 2019 (COVID-19); therefore, the results of 37 clinical trials started in 2020 and completed in 2021 are reviewed and discussed here. These were selected from databases, excluding vaccines, computational studies, in silico, in vitro, and those with hyperimmune sera from recovered patients. We found 34 drugs, one vitamin, and one herbal remedy with pharmacological activity against symptomatic COVID-19. They reduced mortality, disease progression, or recovery time. For each treatment, the identifier and type of trial, the severity of the disease, the sponsor, the country where the trial was conducted, and the trial results are presented. The drugs were classified according to their mechanism of action. Several drugs that reduced mortality also reduced inflammation in the most severe cases. These include some that are not considered anti-inflammatory, such as Aviptadil, pyridostigmine bromide, anakinra, imatinib, baricitinib, and bevacizumab, as well as the combination of ivermectin, aspirin, dexamethasone, and enoxaparin. Nigella sativa seeds with honey have also been reported to have therapeutic activity. On the other hand, tofacitinib, novaferon with ritonavir, and lopinavir were also effective, as well as in combination with antiviral therapies such as danoprevir with ritonavir. The natural products colchicine and Vitamin D3 were only effective in patients with mild-to-moderate COVID-19, as was hydroxychloroquine. Drug repositioning has been the main tool in the search for effective therapies by expanding the pharmacological options available to patients.

01 Sep 2023·International Immunopharmacology

Novaferon gene modification promotes NK92 cell anti-tumor activity

Article

Author: Pu, Luya ; Li, Fan ; Yu, Bingxin ; Meng, Qingyu ; Zhang, Wanze ; Liu, Bin

With significant developments in chimeric antigen receptor T-cell therapy, adoptive immunotherapy has unlocked new levels of treatment for malignancies. Natural killer (NK) cells are promising alternative immune effector cells for this strategy. Multiple anti-tumor therapies are largely dependent on type I interferon (IFN) signaling. Type I IFNs enhance NK cell cytotoxicity. Novaferon (nova) is an unnatural, novel IFN-like protein produced by gene shuffling of IFN-α with strong biological activity. To augment the antitumor activity of NK cells, we generated NK92-nova cells that stably express nova. We found that NK92-nova cells mediated enhanced pan-cancer antitumor activity compared to NK92-vec cells. The increased antitumor activity was associated with the enhanced secretion of cytokines, such as IFN-γ, perforin, and granzyme B. Meanwhile, most of the activating receptors were upregulated in the NK92-nova cells. After co-culture with NK92-nova cells, the expression of NKG2D ligands on the HepG2 cells increased, resulting in an enhanced susceptibility of HepG2 cells to NK92 cell-mediated cytolysis. NK92-nova cells significantly inhibited HepG2 tumor growth in a xenograft model without systemic toxicity. Therefore, NK92-nova cells are a novel and safe strategy for cancer immunotherapy.

10 Jun 2022·China CDC weekly

Novaferon Effectively Inhibits Ancestral SARS-CoV-2 and Omicron Variant in Vitro, 2022.

Article

Author: Ye, Fei ; Ren, Jiao ; Huang, Baoying ; Tan, Wenjie ; Deng, Yao ; Zhao, Li

IntroductionTo identify Novaferon (Nova), a novel recombinant protein of interferon (IFN)-α, antiviral activity against ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Omicron variant in vitro.MethodsVero cells were infected with SARS-CoV-2 and Omicron variant in a biosafety level-3 laboratory. And viral replications were accessed using quantitative real-time reverse transcription polymerase chain reaction (RT-PCR).ResultsResults demonstrated that Nova has effective inhibition against ancestral SARS-CoV-2 and Omicron variant in vitro.DiscussionThe in vivo effects of Nova need to be further tested in animal models. And large-scale randomized double-blind clinical trials are needed to reveal its potentially clinical application.

100 Deals associated with Recombinant cytokine gene derived protein(Genova, Inc.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	S01AD05	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hepatitis B	China	Genova BIOTECH(Qingdao) Co., Ltd.	12 Apr 2018

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 2	China	Genova BIOTECH(Qingdao) Co., Ltd.	30 Jan 2022
Neoplasms	Phase 2	China	GENOVA, Inc. (Japan)	30 Jan 2022
Neuroendocrine carcinoma of thymus	Phase 2	China	Beijing Genova Biotech Co., Ltd.	09 Jul 2015
Melanoma	Phase 2	China	Beijing Genova Biotech Co., Ltd.	10 Aug 2011
Pancreatic Cancer	Phase 2	China	Beijing Genova Biotech Co., Ltd.	18 Oct 2010
Autoimmune Diseases	Preclinical	China	Beijing Genova Biotech Co., Ltd.	30 Jan 2022
Autoimmune Diseases	Preclinical	China	GENOVA, Inc. (Japan)	30 Jan 2022
COVID-19	Preclinical	Japan	Beijing Genova Biotech Co., Ltd.	25 Mar 2021
Metastatic Colorectal Carcinoma	Preclinical	China	Beijing Genova Biotech Co., Ltd.	01 May 2011
Colorectal Cancer	Preclinical	China	Genova Biotherapeutics, Inc.	20 Apr 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.


No Data

Recombinant cytokine gene derived protein(Genova, Inc.)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation